Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Horizon Pharma stock (HZNP)

Buy Horizon Pharma stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Horizon Pharma is a drug manufacturers - general business based in the US. Horizon Pharma shares (HZNP) are listed on the NASDAQ and all prices are listed in US Dollars. Horizon Pharma employs 2,190 staff and has a trailing 12-month revenue of around $3.6 billion.

Our top picks for where to buy Horizon Pharma stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Best for beginners

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for cash sweep

Go to site
Advanced charts and trading tools
  • Trade stocks, ETFs and equity options without commission and $0 option contract fees
  • Earn up to 8.1% APY on your uninvested cash
  • Get a 1.5% match in cash on transferred assets up to $300 or up to 15 free fractional shares worth between $2 and $2,000

How to buy Horizon Pharma stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – HZNP. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Horizon Pharma stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Finder Score: 4.4 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
Stocks, Options, Mutual funds, ETFs, Alternatives
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
Finder Score: 4.3 / 5: ★★★★★
Stocks, Options, ETFs
Up to 8.10%
Choose a 1.5% match or up to 15 free fractional shares
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Finder Score: 4.2 / 5: ★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Horizon Pharma stock price (NASDAQ: HZNP)

Use our graph to track the performance of HZNP stocks over time.

Horizon Pharma shares at a glance

Information last updated 2023-12-03.
Latest market close$116.30
52-week range$98.80 - $116.38
50-day moving average $110.76
200-day moving average $108.06
Wall St. target price$116.50
PE ratio 61.8617
Dividend yield $0 (0%)
Earnings per share (TTM) $1.88

Is it a good time to buy Horizon Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Horizon Pharma price performance over time

Historical closes compared with the close of $116.3 from 2023-10-09

1 week (2024-07-03) N/A
1 month (2024-06-10) N/A
3 months (2024-04-10) N/A
6 months (2024-01-10) N/A
1 year (2023-07-14) 11.89%
2 years (2022-07-14) 46.38%
3 years (2021-07-14) 22.33%
5 years (2019-07-12) 395.74%

Is Horizon Pharma stock undervalued or overvalued?

Valuing Horizon Pharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Horizon Pharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Horizon Pharma's P/E ratio

Horizon Pharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 62x. In other words, Horizon Pharma shares trade at around 62x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Horizon Pharma's PEG ratio

Horizon Pharma's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Horizon Pharma's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Horizon Pharma's EBITDA

Horizon Pharma's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $669.2 million.

The EBITDA is a measure of a Horizon Pharma's overall financial performance and is widely used to measure a its profitability.

Horizon Pharma financials

Revenue TTM $3.6 billion
Operating margin TTM 17.68%
Gross profit TTM $2.8 billion
Return on assets TTM 4.44%
Return on equity TTM 8.54%
Profit margin 12.02%
Book value $23.20
Market Capitalization $26.6 billion

TTM: trailing 12 months

Horizon Pharma share dividends

We're not expecting Horizon Pharma to pay a dividend over the next 12 months.

Horizon Pharma share price volatility

Over the last 12 months, Horizon Pharma's shares have ranged in value from as little as $98.8 up to $116.38. A popular way to gauge a stock's volatility is its "beta".

HZNP.US volatility(beta: 1.01)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Horizon Pharma's is 1.0114. This would suggest that Horizon Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Horizon Pharma overview

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc. ; Halozyme Therapeutics, Inc. ; Arrowhead Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Horizon Pharma is owned by insiders or institutions?
Currently 1.184% of Horizon Pharma shares are held by insiders and 100.852% by institutions.
How many people work for Horizon Pharma?
Latest data suggests 2,190 work at Horizon Pharma.
When does the fiscal year end for Horizon Pharma?
Horizon Pharma's fiscal year ends in December.
Where is Horizon Pharma based?
Horizon Pharma's address is: 70 St. Stephen?s Green, Dublin, Ireland, 2
What is Horizon Pharma's ISIN number?
Horizon Pharma's international securities identification number is: US44047T1097
What is Horizon Pharma's CUSIP number?
Horizon Pharma's Committee on Uniform Securities Identification Procedures number is: G46188101

More guides on Finder

Ask a Question provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site